Editorial: evolving histological assessment of NASH
- PMID: 31709610
- DOI: 10.1111/apt.15537
Editorial: evolving histological assessment of NASH
Comment in
-
Editorial: evolving histological assessment of NASH. Authors' reply.Aliment Pharmacol Ther. 2019 Dec;50(11-12):1245-1246. doi: 10.1111/apt.15570. Aliment Pharmacol Ther. 2019. PMID: 31709613 No abstract available.
Comment on
-
Standardising the interpretation of liver biopsies in non-alcoholic fatty liver disease clinical trials.Aliment Pharmacol Ther. 2019 Nov;50(10):1100-1111. doi: 10.1111/apt.15503. Epub 2019 Oct 3. Aliment Pharmacol Ther. 2019. PMID: 31583739 Free PMC article.
References
REFERENCES
-
- Rinella ME, Tacke F, Sanyal AJ, Anstee QM., participants of the AEW. Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD. Hepatology. 2019;70:1424-1436.
-
- Sanyal AJ, Friedman SL, McCullough AJ, Dimick-Santos L., American Association for the Study of Liver D, United States F, Drug A. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop. Hepatology. 2015;61:1392-1405.
-
- Cheung A, Neuschwander-Tetri BA, Kleiner DE, et al. Defining improvement in nonalcoholic steatohepatitis for treatment trial endpoints: recommendations from the liver forum. Hepatology. 2019. https://doi.org/10.1002/hep.30672 [Epub ahead of print.]
-
- Rowe IA. The devotion to surrogate outcomes in drug development for liver disease. Nat Rev Gastroenterol Hepatol. 2018;15:1-2.
-
- Pai RK, Kleiner DE, Hart J, et al. Standardising the interpretation of liver biopsies in non-alcoholic fatty liver disease clinical trials. Aliment Pharmacol Ther. 2019;50:1100-1111.
Publication types
MeSH terms
LinkOut - more resources
Medical